Home KEYTRUDA (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
 

Keywords :   


KEYTRUDA (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma

2015-10-09 13:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KEYTRUDA is Currently Approved in 39 Countries, including the United States and throughout the European Union KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a draft recommendation, in the form of a Final Appraisal Determination (FAD), recommending KEYTRUDA (pembrolizumab) as a first-line treatment option for adults with advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-236-1130orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: for advanced health care

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
14.11
14.115
14.11MTGfoil
14.11
14.11sw14000XH 8000
14.11katie
14.11EX 330 HP SAR
14.11 M1
More »